Immunic : Presentation (20250605 Immunic Company+Overview June 2025)
IMUX
Published on 06/05/2025 at 10:28
Developing Selective Oral Therapies in Immunology
NASDAQ: IMUX | June 2025
Dedicated to improving the lives of patients with chronic inflammatory and autoimmune diseases
Innovative pipeline:
First-in-class oral drugs with unique modes of actions for multiple sclerosis and gastrointestinal diseases
Positive MS phase 2 data sets:
Underline neuroprotective effect of Nurr1 activation by vidofludimus calcium
Large commercial opportunity:
$3-7 billion peak sales potential for vidofludimus calcium in MS
Experienced leadership team:
Successfully developed and
commercialized multiple medicines
Financials:
Cash balance of $14.3 million
as of Mar 31, 2025 plus $70.1 million raised in April and May 2025
Leadership Team
Company is Led by an Experienced Management Team
Daniel Vitt, PhD
Chief Executive
Officer
Jason Tardio, MBA
President & Chief
Operating Officer
Andreas Muehler, MD, MBA
Chief Medical
Officer
Hella Kohlhof, PhD Chief Scientific Officer
Glenn Whaley, CPA Chief Financial Officer
Patrick Walsh Chief Business Officer
Inderpal Singh General Counsel
Werner Gladdines Chief Development Officer
Duane Nash, MD, JD, MBA
Executive
Chairman
Advanced Clinical Pipeline
Well Differentiated Programs in Various Phases of Clinical Development
Program Preclinical Phase 1 Phase 2 Phase 3
Relapsing Multiple Sclerosis (RMS) - ENSURE-1 and ENSURE-2 Trials
Key Program Updates
Phase 2 EMPhASIS trial in RRMS successfully completed, significantly reduced brain lesions, encouraging results in reducing disability worsening
Interim analysis of ENSURE program completed, IDMC recommendation to continue trials as planned, both ENSURE trials fully enrolled in May 2025
Progressive Multiple Sclerosis (PMS) - CALLIPER Trial
Ulcerative Colitis (UC) - CALDOSE-1 Trial
CALLIPER trial successfully completed, substantial reductions
in disability worsening
Phase 2 CALDOSE-1 trial in UC completed, effective in 50
weeks maintenance phase
Top-line data for both ENSURE trials expected by end of 2026
Celiac Disease and other Gastrointestinal Disorders
Phase 1/1b trial in healthy volunteers and celiac disease
completed, first proof-of-concept in celiac disease
Dose-dependent increase of endogenous GLP-1 in post hoc
analysis of phase 1b trial in celiac disease
Further clinical testing in preparation
IMU-381 Gastrointestinal Diseases
RRMS: relapsing-remitting multiple sclerosis; IDMC: Independent Data Monitoring Committee; GLP-1: glucagon-like peptide-1
*Additional investigator-sponsored phase 2 RAPID_REVIVE trial of vidofludimus calcium in post COVID syndrome ongoing, sponsoredby University Hospital Frankfurt
Disclaimer
Immunic Inc. published this content on June 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 05, 2025 at 14:27 UTC.